Preview

Нефрология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

КУРЕНИЕ И ПОЧКИ

https://doi.org/10.24884/1561-6274-2018-22-1-9-28

Полный текст:

Аннотация

Табакокурение является основным модифицируемым фактором риска развития сердечно-сосудистых,  респираторных, онкологических заболеваний, преждевременной инвалидности и смертности. В статье обобщены сведения об острых и хронических влияниях табакокурения на состояние почек у здоровых людей, а также  на развитие и прогрессирование хронической болезни почек. Рассматриваются различные механизмы воздействия не только никотина, но и мелкодисперсных компонентов табачного дыма. Обсуждается развитие никотиновой зависимости при использовании основных видов табачных изделий, таких как сигареты, кальянный табак, электронные сигареты.

Об авторах

А. Ш. Румянцев
Санкт-Петербургский государственный университет; Первый Санкт-Петербургского государственный медицинский университет им. И.П. Павлова
Россия

Румянцев Александр Шаликович - профессор, доктор медицинских наук, кафедра факультетской терапии.

199106,  Санкт-Петербург,  21-я  линия  В.О.,  д.  8а, +7 (812) 326-03-26



М. Л. Лындина
Санкт-Петербургский государственный университет
Россия

Мария Леонидовна Лындина - кандидат медицинских наук, кафедра факультетской терапии, ассистент

199106, Санкт-Петербург, 21-я линия В.О., д. 8а, (812) 326-03-26



А. Н. Шишкин
Санкт-Петербургский государственный университет
Россия

Шишкин Александр Николаевич - проф., доктор медицинских наук, кафедра факультетской терапии, заведующий.

199106, Санкт-Петербург, 21-я линия В.О., д. 8а, Тел.: (812) 326-03-26



Список литературы

1. World Development Indicators database, World Bank, 15 December 2017

2. Игнатова О. Сигареты выходят из моды. Российская газета – Федеральный выпуск №7411 (245)

3. WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva: World Health Organization; 2017; 135

4. Gandini S., Botteri E., Iodice S. et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122(1):155-164.

5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266

6. Shibuya K., Ciecierski C., Guindon E. et al. WHO Framework Convention on Tobacco Control. BMJ. 2003;327(7407):154-157

7. Gaworski C.L., Oldham M.J., Wagner K.A. et al. An evaluation of the toxicity of 95 ingredients added individually to experimental cigarettes: approach and methods. Inhal Toxicol. 2011;23 Suppl 1:1-12. doi: 10.3109/08958378.2010.543187

8. Андреева Т.И., Красовский К.С. Табак и здоровье. – Киев, 2004.: 224 с.

9. Neergaard J.M., Singh P., Job J., Montgomery S. Waterpipe smoking and nicotine exposure: a review of the current evidence. Nicotine Tobacco Research. 2007; 9: 987-994

10. Cobb C.O., Ward K.D., Maziak W., Shihadeh A.L., Eisenberg T. Waterpipe tobacco smoking: an emerging health crisis in the United States. American Journal of Health Behaviour; 2010; 34: 275-285

11. O'Connor R.J. Non-cigarette tobacco products: What have we learned and where are we headed? Tob Control . 2012 March; 21(2): 181–190. doi:10.1136/tobaccocontrol-2011-050281

12. Streppel M.T., Boshuizen H.C., Ock M.C. et al. Mortality and life expectancy in relation to long-term cigarette, cigar and pipe smoking: the Zutphen Study. Tob Control. 2007;16(2):107- 113. DOI: 10.1136/tc.2006.017715

13. Rabinoff M., Caskey N., Rissling A. et al. Pharmacological and Chemical Effects of Cigarette Additives. Am J Public Health. 2007; 97(11): 1981–1991. doi: 10.2105/AJPH.2005.078014

14. Huang S.J., Xu Y.M., Lau A.T.Y. Electronic cigarette: A recent update of its toxic effects on humans. J Cell Physiol. 2017 Dec 7. doi: 10.1002/jcp.26352. [Epub ahead of print]

15. Colombo E.S., Davis J., Makvandi M. et al. Effects of nicotine on cardiovascular remodeling in a mouse model of systemic hypertension. Cardiovascular toxicology 2013; 13(4):364-369

16. Golli NE, Jrad-Lamine A, Neffati H et al. Impact of ecigarette refill liquid exposure on rat kidney. Regulatory toxicology and pharmacology. RTP 2016; 77:109-116

17. Rubenstein DA, Hom S, Ghebrehiwet B, Yin W. 2015. Tobacco and e-cigarette products initiate Kupffer cell inflammatory responses. Molecular immunology 67(2 Pt B):652-660

18. Lauterstein D.E., Tijerina P.B., Corbett K. et al. Frontal Cortex Transcriptome Analysis of Mice Exposed to Electronic Cigarettes During Early Life Stages. International journal of environmental research and public health 2016;13(4):417

19. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med. 1994;331(2):123-125

20. Sofuoglu M., LeSage M.G. The Reinforcement Threshold for Nicotine as a Target for Tobacco Control. Drug Alcohol Depend. 2012; 125(1-2): 1–7. doi: 10.1016/j.drugalcdep.2012.04.023

21. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18 DOI: 10.1056/NEJM199601043340103

22. Pinto-Sietsma S.J., Mulder J., Janssen W.M. et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133: 585–591

23. Halimi J.M., Giraudeau B., Vol S. et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000; 58(3):1285-1292

24. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance Panarelli W, De Santo NG: Microalbuminuria in nondiabetic from serum creatinine. Nephron 1976; 16:31–41

25. Halimi J-M., Philippon C., Mimran A. Contrasting renal effects of nicotine in smokers and never-smokers. Nephrol Dial Transplant 1998;13:940–944

26. Bleyer AJ, Shemanski LR, Burke GL et al. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000; 57: 2072–2079

27. Tozawa M, Iseki K, Iseki C, Oshiro S et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956–962

28. Haroun MK, Jaar BG, Hoffman SC et al. ,Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14: 2934–2941

29. Stengel B, Tarver-Carr ME, Powe NR et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479–487

30. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844–850

31. Baggio B, Budakovic A, Perissinotto E et al. Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA).Nephrol Dial Transplant 2005; 20: 114–123

32. Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol 2006; 164: 263–271

33. Ishani A, Grandits GA, Grimm RH et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006; 17: 1444–1452

34. Yamagata K, Ishida K, Sairenchi T et al. Risk factors for chronic kidney disease in a community-based population: a 10year follow-up study. Kidney Int 2007; 71: 159–166

35. Yamamoto R, Nagasawa Y, Shoji T et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 2010; 56: 313–324

36. Nogueira JM, Haririan A, Jacobs SC et al. Cigarette smoking, kidney function, and mortality after live donor kidney transplant. Am J Kidney Dis 2010; 55: 907–915

37. Scott L.J., Warram J.H., Hanna L.S. et al. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001; 50: 2842–2849

38. de Boer I.H., Sibley S.D., Kestenbaum B. Et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007; 18: 235–243

39. Perry Jr. H.M., Miller J.P., Fornoff J.R et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (4 Pt 1): 587–594

40. Sud M., Tangri N., Levin A. et al. CKD stage at nephrology referral and factors influencing the risks of ESRD and death. Am J Kidney Dis. 2014;63(6):928-36. doi: 10.1053/j.ajkd.2013.12.008

41. Obi Y, Kimura T, Nagasawa Y et al. Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol 2010; 5:1558–1565

42. Orth S.R., Stockmann A., Conradt C. et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54: 926–931

43. Khalil M.A.M., Tan J., Khamis S. et al. Cigarette Smoking and Its Hazards in Kidney Transplantation Adv Med 2017;2017:6213814. doi: 10.1155/2017/6213814;

44. Sözen F., Aydemir S., Erdal R., Haberal M. Smoking Behaviors of Renal Transplant Recipients: An Analysis of 113 Patients. Exp Clin Transplant 2016;14(Suppl 3):95-99;

45. Underwood P.W., Sheetz K.H., Cron D.C. et al. Cigarette smoking in living kidney donors: donor and recipient outcomes. Clin Transplant. 2014;28(4):419-422. doi: 10.1111/ctr.12330

46. Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Committee on Standards and Practice Parameters. Anesthesiology. 2012;116(3):522-538. doi: 10.1097/ALN.0b013e31823c1067

47. Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation. 2005; 79 (6 Suppl): S53-66

48. Keles M., Avsar U., Avsar Z. et al. Effect of kidney transplantation on smoking habits of kidney donors. Transplantation Proceedings 2015; 47 (5): 1302-1305

49. Kasiske B.L., Chakkera H.A., Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J. of the American Society of Nephrology 2000; 11 (9): 1735-1743

50. Global Adult Tobacco Survey Collaborative Group. Tobacco Questions for Surveys: A Subset of Key Questions from the Global Adult Tobacco Survey (GATS), 2nd Edition. Atlanta, GA: Centers for Disease Control and Prevention, 2011: 42

51. Howard R. Microrisks for medical decision analysis. Int J Technol Assess Health Care 1989; 5: 357–370

52. Spiegelhalter D. How old are you, really? Communicating chronic risk through 'effective age' of your body and organs. BMC Med Inform Decis Mak. 2016 Aug 5;16:104. doi: 10.1186/s12911-016-0342-z

53. Pan A., Wang Y., Talaei M. et al. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(12):958-67. doi: 10.1016/S2213-8587(15)00316-2

54. Aucella F., Cignarelli M., Lamacchia O., Gesualdo L. Environment, Smoking, Obesity, and the Kidney In: Claudio Ronco Rinaldo Bellomo John Kellum, eds. Critical Care Nephrology, 2nd ed. Saunders, 2009: 1320-1324

55. Benowitz N.L., Hukkanen J., Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacology. 2009; 192: 29-60

56. Moran V.E. Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption. Front Pharmcol. 2012; 3: 173

57. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79-115

58. Loukola A., Hallfors J., Korhonen T., Kaprio J. Genetics and smoking. Curr Addict Rep. 2014; 1: 75-82

59. Mishra A., Chaturvedi P., Datta S. et al. Harmful effects of nicotine. Indian J Med Paediatr Oncol. 2015 Jan-Mar;36(1):24-31. doi: 10.4103/0971-5851.151771

60. Liu C.C., Yeh H.I. Nicotine: A Double-Edged Sword in Atherosclerotic Disease. Acta Cardiol Sin. 2014;30(2):108-113

61. Jaimes E.A., Tian R.X., Joshi M.S., Raij L. Nicotine augments glomerular injury in a rat model of acute nephritis. Am J Nephrol. 2009;29(4):319-26. doi: 10.1159/000163593

62. Arany I., Grifoni S., Clark J. S., Csongradi E., Maric C., Juncos L. A. (2011) Chronic nicotine exposure exacerbates acute renal ischemic injury. Am. J. Physiol. Renal Physiol. 301, F125– F133 doi: 10.1152/ajprenal.00041.2011

63. Ateyya H., Nader M.A., Attia G.M., El-Sherbeeny N.A. Influence of alpha-lipoic acid on nicotine-induced lung and liver damage in experimental rats. Can J Physiol Pharmacol. 2017;95(5):492-500. doi: 10.1139/cjpp-2016-0366

64. Biondo-Simões Mde L., Spelling N.W., Ioshii S. et al. The influence of nicotine on the population of fibroblasts in cutaneous scars in rats. Acta Cir Bras. 2009;24(6):466-470

65. Holbourn K.P., Acharya K.R., Perbal B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci. 2008;33(10):461-473. doi: 10.1016/j.tibs.2008.07.006

66. Takeuchi H., Kubota S., Murakashi E. et al. Nicotineinduced CCN2: from smoking to periodontal fibrosis. J. Dent. Res 2010; 89, 34-39

67. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27(1):27-36

68. Coburn R.F. The measurement of endogenous carbon monoxide production. J Appl Physiol 2012; 112: 1949–1955

69. Stamellou E., Storz D., Botov S. et al. Different design of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative differences in biological activities in terms of toxicity and inflammation. Redox Biol. 2014;2:739-748. doi: 10.1016/j.redox.2014.06.002

70. Kourti M., Jiang W.G., Cai J. Aspects of Carbon Monoxide in Form of CO-Releasing Molecules Used in Cancer Treatment: More Light on the Way. Oxid Med Cell Longev. 2017;2017:9326454. doi: 10.1155/2017/9326454

71. Qiao L., Zhang N., Huang J.L., Yang X.Q. Carbon monoxide as a promising molecule to promote nerve regeneration after traumatic brain injury. Med Gas Res. 2017;7(1):45-47. doi: 10.4103/2045-9912.202909

72. Левченкова О.С., Новиков В.Е. Индукторы регуляторного фактора адаптации к гипоксии. Российский медико-биологический вестник им. академика И.П. Павлова 2014; (2): 133-143

73. Tanaka T., Nangaku M. The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(1):43-50. doi: 10.1097/MNH.0b013e3283328eed

74. Бобкова И.Н., Козловская Л.В., Рамеева А.С. и др. Клиническое значение определения в моче маркеров эндотелиальной дисфункции и факторов ангиогенеза в оценке тубулоинтерстициального фиброза при хроническом гломерулонефрите. Терапевтический архив 2007; 79 (6): 10-16

75. Orr S.E., Bridges C.C. Chronic Kidney Disease and Exposure to Nephrotoxic Metals. Int J Mol Sci. 2017;18(5). pii: E1039. doi: 10.3390/ijms18051039

76. Li W.J., Yang C.L., Chow K.C., Kuo T.W. Hexavalent chromium induces expression of mesenchymal and stem cell markers in renal epithelial cells. Mol Carcinog. 2016;55(2):182-192. doi: 10.1002/mc.22268

77. Jan A.T., Azam M., Siddiqui K. et al. Heavy Metals and Human Health: Mechanistic Insight into Toxicity and Counter Defense System of Antioxidants. Int J Mol Sci. 2015;16(12):29592-630. doi: 10.3390/ijms161226183

78. Carocci A., Catalano A., Lauria G. Lead Toxicity, Antioxidant Defense and Environment. Rev Environ Contam Toxicol. 2016;238:45-67. doi: 10.1007/398_2015_5003

79. Modaresi A., Nafar M., Sahraei Z. Oxidative stress in chronic kidney disease. Iran J Kidney Dis. 2015;9(3):165-179

80. George B, You D, Joy MS, Aleksunes LM. Adv Drug Deliv Rev. 2017;116:73-91. doi: 10.1016/j.addr.2017.01.005

81. Alevriadou B.R., Shanmughapriya S., Patel A. et al. J R Soc Interface. 2017;14(137). pii: 20170672. doi: 10.1098/rsif.2017.0672

82. Островская С.С. Токсические эффекты кадмия. Вестник проблем биологии и медицины. 2014; 3(2): 33-37

83. Magee P.N., Farber E. Toxic liver injury and carcinogenesis. Methylation of rat-liver nucleic acids by dimethylnitrosamine in vivo. Biochem J. 1962; 83:114-124

84. Lin X., Wood C.G., Shao L. et al. Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer. 2007;110:282–288

85. Orth S.R., Hallan S.I. Smoking: A Risk Factor for Progression of Chronic Kidney Disease and for Cardiovascular Morbidity and Mortality in Renal Patients—Absence of Evidence or Evidence of Absence? Clin J Am Soc Nephrol 3: 226–236, 2008. doi: 10.2215/CJN.03740907


Для цитирования:


Румянцев А.Ш., Лындина М.Л., Шишкин А.Н. КУРЕНИЕ И ПОЧКИ. Нефрология. 2018;22(1):9-28. https://doi.org/10.24884/1561-6274-2018-22-1-9-28

For citation:


Rumyantsev A.S., Lyndina M.L., Shishkin A.N. SMOKING AND KIDNEYS. Nephrology (Saint-Petersburg). 2018;22(1):9-28. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-1-9-28

Просмотров: 6


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)